2025
Cardiac Magnetic Resonance Imaging in Immune Checkpoint Inhibitor–Related Myocarditis
Hammer M, Tysarowski M, Fuss C, Bader A. Cardiac Magnetic Resonance Imaging in Immune Checkpoint Inhibitor–Related Myocarditis. Echocardiography 2025, 42: e70131. PMID: 40067334, DOI: 10.1111/echo.70131.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsImmune checkpoint inhibitorsCardiac magnetic resonance imagingMagnetic resonance imagingAssociated with immune-related adverse eventsCardiac immune-related adverse eventsMechanisms of immune checkpoint inhibitorsICI-associated myocarditisICI-related myocarditisResonance imagingPersonalized cancer immunotherapySevere cardiovascular complicationsImmune tolerance pathwayCheckpoint inhibitorsCancer immunotherapyCardiac complicationsCombination therapyTumor cytotoxicityClinical presentationCardiovascular complicationsAdverse eventsTherapeutic efficacyOncological treatmentTherapeutic strategiesMyocarditis
2022
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu S, Wang J, Shah A, Tannir N, Campbell M, Gibbons D, Cascone T, Lu C, Blumenschein G, Altan M, Lim B, Valero V, Loghin M, Tu J, Westin S, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi H, Hwu P, Oliva I, Davies M, Patel S, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications 2022, 13: 1970. PMID: 35413951, PMCID: PMC9005525, DOI: 10.1038/s41467-022-29539-3.Peer-Reviewed Original ResearchConceptsCD8+ T cellsImmune-related adverse eventsImmune checkpoint inhibitorsT cellsCheckpoint inhibitorsAssociated with immune-related adverse eventsPD-1 inhibitor therapyT-cell axisEnhanced Th17Antitumor immunityCTLA-4PD-1Inhibitor therapyImmunomodulatory therapyTCR repertoirePredictive biomarkersPeripheral bloodMyeloid cellsAdverse eventsCell signaturesCancer therapyInflammatory arthritisInflamed jointsTherapyTherapeutic target
2018
A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab
Friedlander P, Wood K, Wassmann K, Christenfeld A, Bhardwaj N, Oh W. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab. Journal For ImmunoTherapy Of Cancer 2018, 6: 90. PMID: 30227886, PMCID: PMC6145108, DOI: 10.1186/s40425-018-0408-9.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsAnti-PD-1/PD-L1 immunotherapyNegative predictive valuePositive predictive valueImmune checkpoint blockadeGrade 2Checkpoint blockadeAssociated with immune-related adverse eventsPatients treated with immune checkpoint blockadeFrequent immune-related adverse eventsClinically relevant predictive biomarkersImmune checkpoint blockade resultsGene expression changesSevere diarrheaPredictive valueDays post-treatment initiationCTLA-4 pathwayPhase II studyPhase III studyPost-treatment initiationGenes associated with inflammationImmune system modulationAnti-CTLA4IrAE severityAdvanced melanoma
2017
Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series
Kim S, Tayar J, Trinh V, Suarez-Almazor M, Garcia S, Hwu P, Johnson D, Uemura M, Diab A. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Annals Of The Rheumatic Diseases 2017, 76: 2061-2064. PMID: 28830882, DOI: 10.1136/annrheumdis-2017-211560.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsImmune checkpoint inhibitorsCheckpoint inhibitorsReceptor antibodiesAssociated with immune-related adverse eventsMild immune-related adverse eventsEffective alternative to corticosteroidsEfficacy of ICI therapyICI-induced inflammatory arthritisImmune checkpoint inhibitor therapyAnti-IL-6 receptor antibodyAlternative to corticosteroidsTreated with corticosteroidsTreated with tocilizumabTumor necrosis factor-aImmune dampening effectsInflammatory side effectsAlternative therapeutic strategiesFood and Drug AdministrationTreatment of rheumatoid arthritisJuvenile idiopathic arthritisAntitumour responseICI therapyTNFa inhibitorsCheckpoint inhibition
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply